✦ LIBER ✦

Phase I pharmacokinetic and biodistribution study with escalating doses of223Ra-dichloride in men with castration-resistant metastatic prostate cancer

✍ Scribed by Carrasquillo, Jorge A.; OâDonoghue, Joseph A.; Pandit-Taskar, Neeta; Humm, John L.; Rathkopf, Dana E.; Slovin, Susan F.; Williamson, Matthew J.; Lacuna, Kristine; Aksnes, Anne-Kirsti; Larson, Steven M.; Scher, Howard I.; Morris, Michael J.

Book ID: 120503544
Publisher: Springer
Year: 2013
Tongue: English
Weight: 426 KB
Volume: 40
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00259-013-2427-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-escalation and pharmacokine

Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer

✍ Mukai, Hirofumi; Takahashi, Shunji; Nozawa, Masahiro; Onozawa, Yusuke; Miyazaki, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 295 KB

P124 Long-term safety of radium-223 dich

P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

✍ Nilsson, S; Schrader, A.J.; Kliment, J.; Solberg, A.; Franzén, L.; Bottomley, D. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 66 KB

714 PAIN AND QUALITY OF LIFE (QOL) ANALY

714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES

✍ Tomblyn, Michael; Nilsson, Sten; Vogelzang, Nicholas; Sartor, A. Oliver; Cislo, 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

Estimating the Economic Impact of Radium

Estimating the Economic Impact of Radium Ra 223 Dichloride (Radium-223) in Treatment of Castration-Resistant Prostate Cancer (CRPC) with Symptomatic Bone Metastases and No Known Visceral Metastatic Disease

✍ Valderrama, A.; Bilir, S.P.; Wehler, E.A.; Seal, B.S.; Wen, L.; Yaldo, A.; Munak 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

A phase I study of zibotentan (ZD4054) i

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

✍ William R. Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 153 KB

Biomarkers in the Management and Treatme

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

✍ Andrew J. Armstrong; Mario A. Eisenberger; Susan Halabi; Stephane Oudard; David 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 770 KB